Adial Pharmaceuticals Doses First Patient In Pharmacokinetics Study Of AD04 For Treatment Of Alcohol Use Disorder
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has dosed the first patient in a pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This marks a significant milestone in the development of AD04.
June 05, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals has dosed the first patient in a pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. This milestone could positively impact investor sentiment and the stock price in the short term.
Dosing the first patient in a pharmacokinetics study is a significant step in the drug development process. This progress can boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100